Study shows Wellmune® reduces upper respiratory tract infection (URTI) symptoms among marathoners.
Study: Texas Marathon
This study confirmed previous clinical research showing that Wellmune supports the immune system of athletes. In this case, Wellmune showed health benefits for runners who had completed a marathon, for whom post-race URTIs are common.
Study Protocol
| Study Site | Department of Health and Human Performance, University of Houston, USA |
| Population | 182 runners (96 men, 86 women) who completed the 2011 LiveStrong Marathon in Austin, Texas with an average finish time of 4 hours. |
| Age | 29-46 (average 34 years) |
| Design | Randomized, double-blinded, placebo-controlled, parallel arm study |
| Duration | Four weeks |
| Serving |
Participants were split into three groups, and consumed one of the following once daily:
|
| Details | Incidence of URTI symptoms was assessed using the clinically-validated WURSS-44 survey. |
Results
- Wellmune supplementation significantly reduced the number of days that subjects reported both general health problems as well as cold/flu symptoms.
Participants taking Wellmune had 40% reduction in URTI symptoms.
Additional Information
Based on previous studies by the University of Houston, it is reasonable to speculate that the improvements associated with Wellmune were due to alterations in monocytes, plasma cytokines and improved mucosal immunity.
Prevamune™ contains the clinical strength of Wellmune® used in scientific studies.
